Welcome to our dedicated page for Guardant Health news (Ticker: $GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.
Guardant Health reported a 31% increase in revenue for the first quarter of 2024 compared to the same period in 2023. The company achieved significant revenue growth in precision oncology, driven by increased testing volume and reimbursement rates. Despite a decrease in free cash flow, Guardant Health raised its 2024 revenue guidance to $675-$685 million, showcasing a positive outlook for the year. The company also highlighted key milestones achieved in clinical data validation, product launches, and publication impact.
Guardant Health, Inc. (Nasdaq: GH) will participate in upcoming investor conferences including the BofA Securities 2024 Healthcare Conference and Leerink Partners 2024 Healthcare Crossroads Conference. Interested parties can access live and archived webcasts of the sessions on the company website.
Guardant Health, Inc. (Nasdaq: GH) has achieved a significant milestone by surpassing 500 peer-reviewed publications featuring its technology in esteemed scientific journals. These publications have had a profound impact on the oncology field, validating Companion Diagnostic claims and driving changes in NCCN guidelines. The company's accelerated publication rate of approximately 100 publications annually highlights its leadership in liquid biopsy research.